MAIA Biotechnology

IN THE PRESS

Press Releases

MAIA’s Ateganosine Surges Ahead with Breakthrough Momentum as Pivotal Phase 3 Trial Initiates

December 12, 2025

·

5 min read

Press Releases

MAIA Biotechnology Announces First Patient Dosed in THIO-104 Phase 3 Pivotal Trial Evaluating Ateganosine as Third-Line Treatment for Advanced Non-Small Cell Lung Cancer

December 12, 2025

·

6 min read

Press Releases

MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential

December 12, 2025

·

3 min read

Press Releases

MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach

December 11, 2025

·

6 min read

Press Releases

MAIA Biotechnology Announces Open Market Purchases by CEO and Directors

December 2, 2025

·

3 min read

Press Releases

MAIA Biotechnology Highlights Ongoing Momentum of Ateganosine Clinical Program at SITC 2025

November 24, 2025

·

8 min read

Press Releases

MAIA Biotechnology CEO Presents Telomere Targeting Efficacy at Romania’s 2025 Smart Diaspora Conference on Oncology Research and Innovation

November 21, 2025

·

6 min read

Press Releases

MAIA Biotechnology Presents Trial in Progress Poster at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

October 28, 2025

·

7 min read

Press Releases

MAIA Biotechnology Details 30-Month Patient Survival in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

October 24, 2025

·

6 min read

Press Releases

MAIA Biotechnology Announces $736,600 Private Placement

October 14, 2025

·

4 min read

JOBS